Abstract
Autologous hematopoietic stem cell transplantation is the standard treatment for a wide variety of malignancies. At present, most hematopoietic progenitor/stem cell (HPC) collections are collected from the peripheral blood via leukapheresis following chemotherapy and/or growth factor-mediated mobilization. Most mobilization regimens consist of chemotherapy followed by one or more growth factors such as G-CSF, GM-CSF, or plerixafor. Occasionally a subset of patients will prove unable to mobilize effectively and will not collect at least 2.0 × 3106 CD34+ cells/kg, the number of HPC currently considered to be appropriate for transplant in order to achieve timely engraftment and recovery of hematopoiesis. When this occurs it may be necessary to either remobilize, possibly with a different method, or to do a marrow harvest. Recent research has explored the benefits of using HPC outside of the oncology arena, notably in the area of cardiac regeneration following infarction, making the subject of mobilization potentially important to many areas of medicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tricot G, Jagannath S, Vesole D et al (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588–596
Morris CL, Siegel E, Barlogie B et al (2003) Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 120:413–423
Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547–2555
Rosenbaum ER, O’Connell B, Cottler-Fox M (2012) Validation of a formula for predicting daily CD34(+) cell collection by leukapheresis. Cytotherapy 14(4):461–466
Rivadeneyra-Espinoza L, Perez-Romano B, Gonzalez-Flores A et al (2006) Instrument- and protocol-dependent variation in the enumeration of CD34+ cells by flow cytometry. Transfusion 46:530–536
Bender JG, To LB, Williams S et al (1992) Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1:329–341
Weaver CH, Hazelton B, Birch R et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961–3969
Suh C, Kim S, Kim SH et al (2004) Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 44:1762–1768
Park KU, Kim SH, Suh C et al (2001) Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 67:42–47
Dao MA, Arevelo J, Nolta JA (2003) Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood 101:112–118
Hess DA, Wirthlin L, Craft TP et al (2006) Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 107:2162–2169
Rosenbaum ER, Nakagawa M, Pesek G et al (2009) A 15 hour extended dosing-collection interval for Plerixafor is at least as effective as the standard 10 hour interval. Blood 114:2152
Product information. Leukine (sargramostim). Seattle, WA: Bayer Healthcare Pharmaceuticals, April 2008
Product information. Neupogen (filgrastim). Thousand Oaks, CA: Amgen Inc., 1991–1996.
Product information. Mozobil (plerixafor). Cambridge, MA: Genzyme Corporation, December 2008
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Pesek, G., Cottler-Fox, M. (2012). Hematopoietic Stem Cell Mobilization: A Clinical Protocol. In: Kolonin, M., Simmons, P. (eds) Stem Cell Mobilization. Methods in Molecular Biology, vol 904. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-943-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-61779-943-3_5
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-942-6
Online ISBN: 978-1-61779-943-3
eBook Packages: Springer Protocols